A carregar...
Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader
Endocrine therapy, using tamoxifen or an aromatase inhibitor, remains first-line treatment for estrogen receptor (ESR1) positive breast cancer. However, tumor resistance limits the duration of response. The clinical efficacy of fulvestrant, a Selective Estrogen Receptor Degrader (SERD) that triggers...
Na minha lista:
| Publicado no: | Endocr Relat Cancer |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4545300/ https://ncbi.nlm.nih.gov/pubmed/26162914 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-15-0287 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|